Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: A single center study

Canadian Journal of Urology

Volumn 22, Issue 2, 2015, Pages 7703-7708

  Cattarino, Susanna ^a   Seisen, Thomas ^a,b   Drouin, Sarah J ^a   Renard Penna, Raphaële ^a   Leon, Priscilla ^a,b   Comperat, Eva ^a   Mozer, Pierre ^a   Cussenot, Olivier ^a,b   Rouprêt, Morgan ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Hydroxymethylglutaryl CoA reductase inhibitors; Prostate specific antigen; Prostatic neoplasm; Recurrence; Survival

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

AGED; BIOPSY; BLOOD; CANCER STAGING; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84932107893     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.
2. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71.
3. Boorjian SA, Eastham JA, Graefen M et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012;61(4):664-675.
4. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-1278.
5. Mann D, Reynolds K, Smith D et al. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42(9):1208-1215.
6. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120(4):833-843.
7. Carlberg M, Dricu A, Blegen H et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulinlike growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem 1996;271(29):17453-17462.
8. Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005;5(8):579-594.
9. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4(12): 977-987.
10. Wong WW, Dimitroulakos J, Minden MD et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16(4):508-519.
11. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012;18(13):3524-3531.
12. Morote J, Celma A, Planas J et al. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci 2014;15(8):13615-13623.
13. Ishak-Howard MB, Okoth LA, Cooney KA. Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer. Urology 2014;83(6):1356-1361.
14. Chao C, Jacobsen SJ, Xu L et al. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int 2013;111(6):954-962.
15. Misrai V, Do C, Lhez JM et al. [Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?]. Prog Urol 2012;22(5):273-278.
16. Rieken M, Kluth LA, Xylinas E et al. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis 2013;16(4):367-371.
17. Ritch CR, Hruby G, Badani KK et al. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int 2011;108(8 Pt 2):E211-E216.
18. Hurtes X, Roupret M, Vaessen C et al. Anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial. BJU Int 2012;110(6):875-883.
19. Murtola TJ. Impact of statins on genitourinary cancer outcomes: the promise and the challenge. J Urol 2014;191(4):889-890.
20. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008;123(4):899-904.
21. Dale KM, Coleman CI, Henyan NN et al. Statins and cancer risk: a meta-analysis. JAMA 2006;295(1):74-80.
22. Mondul AM, Han M, Humphreys EB et al. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011;185(4):1268-1273.
23. Freedland SJ, Hamilton RJ, Gerber L et al. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis 2013;16(3):254-259.
24. Platz EA, Tangen CM, Goodman PJ et al. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol 2014:192(2):379-384.
25. Flick ED, Habel LA, Chan KA et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16(11):2218-2225.
26. Jacobs EJ, Rodriguez C, Bain EB et al. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007;16(11):2213-2217.
27. Hamilton RJ, Banez LL, Aronson WJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010;116(14):3389-3398.
28. Lustman A, Nakar S, Cohen AD et al. Statin use and incident prostate cancer risk: does the statin brand matter? A populationbased cohort study. Prostate Cancer Prostatic Dis 2014;17(1):6-9.
29. Allott EH, Howard LE, Cooperberg MR et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database. BJU Int 2014:114(5):661-666.
30. Hamilton RJ, Goldberg KC, Platz EA et al. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008;100(21):1511-1518.